CLINICAL AND ECONOMIC ADVANTAGES OF THE USE OF NUMETA G13E FOR PARENTERAL NUTRITION OF PREMATURE NEWBORNS IN COMPARISON WITH THE SIMULTANEOUS USE OF AMINO ACIDS SOLUTIONS, FAT EMULSIONS AND GLUCOSE

Abstract

Introduction. In the first days of life, all premature newborns depend on parenteral nutrition (PN). At the same time, it can be associated with an increased incidence of bacterial and fungal sepsis, mechanical complications associated with venous access, errors in appointment, metabolic disorders.Aim. Carry out clinical, pharmacoeconomic evaluation and affect the budget of Numeta G13E use in premature newborns with weight less than1500 g in comparison with separate one-time use of amino acids solutions, fat emulsion and glucose.Materials and methods. The clinical effectiveness of standardized PN and individualized PN in premature newborns was analyzed. Pharmacoeconomic analysis was performed according to the cost-effectiveness model. The impact of 2 technologies on the budget with the timeline of 5 years was calculated. 3 scenarios of influence on the budget were developed.Results. The "cost-effectiveness ratio" of individualized PN in patients with weight <1000 g was 126,052.94 UAH, for patients with weight ≤1500 g was 113,312.43 UAH, "cost-effectiveness ratio" for standardized PN was 132 347,00 and 114 373,67 UAH respectively. The cost per additional unit of efficiency (ICER) was 205,717.71 UAH for newborns with weight <1000 g and 126,744.71 UAH for newborns with weight ≤1500 g.Conclusions. It was revealed that the use of Numeta G13E is a cost-effective technology with an ICER that does not exceed the probable threshold of "willingness to pay" of 3 GDP per capita in Ukraine. Analysis of sensitivity towards key parameters changes (the cost of drugs, the likelihood of bloodstream infections and the duration of PN) revealed the stability of pharmacoeconomic calculations.